BNF:

8.1.5

Status:

Red

Decision Date:

January 2017

Comments

RED:^1,2,3: NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer.

RED ^1,2,3: NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer.

RED^1,2,3: NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. (Decision date  - April 2019)

NHSE commission a new combined pertuzumab and trastuzumab subcutaneous injection, brand name PHESGO®, for all existing pertuzumab and trastuzumab indications as an alternative to IV pertuzumab and trastuzumab.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again